Steven J Siegel

List of Publications by Year
in descending order

145 papers	14,227 citations	25034 57 h-index	20358 116 g-index
150 all docs	150 docs citations	150 times ranked	19152 citing authors

#	Article	IF	Citations
1	Aberrant functional connectivity between reward and inhibitory control networks in pre-adolescent binge eating disorder. Psychological Medicine, 2023, 53, 3869-3878.	4.5	10
2	Regional gray matter abnormalities in pre-adolescent binge eating disorder: A voxel-based morphometry study. Psychiatry Research, 2022, 310, 114473.	3.3	9
3	Early life social instability stress causes lasting cognitive decrement and elevated hippocampal stress-related gene expression. Experimental Neurology, 2022, 354, 114099.	4.1	5
4	Frequency-specific medial septal nucleus deep brain stimulation improves spatial memory in MK-801-treated male rats. Neurobiology of Disease, 2022, 170, 105756.	4.4	4
5	mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia. Molecular Psychiatry, 2020, 25, 750-760.	7.9	39
6	Sociability development in mice with cellâ€specific deletion of the NMDA receptor NR1 subunit gene. Genes, Brain and Behavior, 2020, 19, e12624.	2.2	11
7	A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology. Neuropsychopharmacology, 2020, 45, 1411-1422.	5.4	51
8	High-beta/low-gamma frequency activity reflects top-down predictive coding during a spatial working memory test. Experimental Brain Research, 2019, 237, 1881-1888.	1.5	7
9	Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism. Pharmacology Biochemistry and Behavior, 2019, 181, 93-100.	2.9	37
10	Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 93, 84-92.	4.8	11
11	Parvalbumin Cell Ablation of NMDA-R1 Leads to Altered Phase, But Not Amplitude, of Gamma-Band Cross-Frequency Coupling. Brain Connectivity, 2019, 9, 263-272.	1.7	12
12	Pyramidal cell-selective GluN1 knockout causes impairments in salience attribution and related EEG activity. Experimental Brain Research, 2018, 236, 837-846.	1.5	3
13	Mismatch negativity in preclinical models of schizophrenia. Schizophrenia Research, 2018, 191, 35-42.	2.0	45
14	The nature and consequences of cognitive deficits among tobacco smokers with HIV: a comparison to tobacco smokers without HIV. Journal of NeuroVirology, 2017, 23, 550-557.	2.1	22
15	Amygdala activity associated with social choice in mice. Behavioural Brain Research, 2017, 332, 84-89.	2.2	9
16	Protocadherin 10 alters Î³ oscillations, amino acid levels, and their coupling; baclofen partially restores these oscillatory deficits. Neurobiology of Disease, 2017, 108, 324-338.	4.4	15
17	From provocation to aggression: the neural network. BMC Neuroscience, 2017, 18, 73.	1.9	56
18	GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in theFmr1Knockout Mouse Model of Fragile X Syndrome. ENeuro, 2017, 4, ENEURO.0380-16.2017.	1.9	66

#	Article	IF	Citations
19	Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models. Frontiers in Behavioral Neuroscience, 2016, 10, 136.	2.0	36
20	Lysosomal iron modulates NMDA receptor-mediated excitation via small GTPase, Dexras1. Molecular Brain, 2016, 9, 38.	2.6	47
21	Metabotropic Glutamate Receptor 5 as a Point of Convergence for Models of Obsessive-Compulsive Disorder and Autism Spectrum Disorder. Biological Psychiatry, 2016, 80, 504-506.	1.3	3
22	Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism.. Behavioral Neuroscience, 2015, 129, 389-398.	1.2	54
23	Mouse Model of Chromosome 15q13.3 Microdeletion Syndrome Demonstrates Features Related to Autism Spectrum Disorder. Journal of Neuroscience, 2015, 35, 16282-16294.	3.6	51
24	The Role of Nicotine in Schizophrenia. International Review of Neurobiology, 2015, 124, 23-78.	2.0	37
25	PDE-4 Inhibition Rescues Aberrant Synaptic Plasticity inDrosophilaand Mouse Models of Fragile X Syndrome. Journal of Neuroscience, 2015, 35, 396-408.	3.6	53
26	EEG biomarkers of target engagement, therapeutic effect, and disease process. Annals of the New York Academy of Sciences, 2015, 1344, 12-26.	3.8	30
27	Mechanisms of Bacterial Colonization of the Respiratory Tract. Annual Review of Microbiology, 2015, 69, 425-444.	7.3	154
28	Mice with subtle reduction of NMDA NR1 receptor subunit expression have a selective decrease in mismatch negativity: Implications for schizophrenia prodromal population. Neurobiology of Disease, 2015, 73, 289-295.	4.4	52
29	Pyramidal Cell Selective Ablation of N-Methyl-D-Aspartate Receptor 1 Causes Increase in Cellular and Network Excitability. Biological Psychiatry, 2015, 77, 556-568.	1.3	89
30	Clearance of Pneumococcal Colonization in Infants Is Delayed through Altered Macrophage Trafficking. PLoS Pathogens, 2015, 11, e1005004.	4.7	31
31	Prospective MEG biomarkers in ASD: pre-clinical evidence and clinical promise of electrophysiological signatures. Yale Journal of Biology and Medicine, 2015, 88, 25-36.	0.2	32
32	Convergence of circuit dysfunction in ASD: a common bridge between diverse genetic and environmental risk factors and common clinical electrophysiology. Frontiers in Cellular Neuroscience, 2014, 8, 414.	3.7	31
33	TLR2 Signaling Decreases Transmission of Streptococcus pneumoniae by Limiting Bacterial Shedding in an Infant Mouse Influenza A Co-infection Model. PLoS Pathogens, 2014, 10, e1004339.	4.7	63
34	Influenza Promotes Pneumococcal Growth during Coinfection by Providing Host Sialylated Substrates as a Nutrient Source. Cell Host and Microbe, 2014, 16, 55-67.	11.0	209
35	Animal Models of Psychosis: Current State and Future Directions. Current Behavioral Neuroscience Reports, 2014, 1, 100-116.	1.3	49
36	Parvalbumin Cell Ablation of NMDA-R1 Causes Increased Resting Network Excitability with Associated Social and Self-Care Deficits. Neuropsychopharmacology, 2014, 39, 1603-1613.	5.4	96

#	Article	IF	Citations
37	Male and female mice differ for baseline and nicotine-induced event related potentials.. Translational Issues in Psychological Science, 2014, 1, 35-46.	1.0	0
38	Brain activity and emotional processing in smokers treated with varenicline. Addiction Biology, 2013, 18, 732-738.	2.6	21
39	Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expression. Psychopharmacology, 2013, 227, 639-649.	3.1	19
40	Capacity, Confidentiality and Consequences: Balancing Responsible Medical Care With Mental Health Law. Current Psychiatry Reports, 2013, 15, 380.	4.5	1
41	Knockout of <scp>NMDA</scp> Receptors in Parvalbumin Interneurons Recreates Autismâ€Like Phenotypes. Autism Research, 2013, 6, 69-77.	3.8	87
42	Animal models and measures of perceptual processing in Schizophrenia. Neuroscience and Biobehavioral Reviews, 2013, 37, 2092-2098.	6.1	34
43	Electroencephalographic and early communicative abnormalities in Brattleboro rats. Physiological Reports, 2013, 1, e00100.	1.7	6
44	The scent of salience â€" Is there olfactory-trigeminal conditioning in humans?. NeuroImage, 2013, 77, 93-104.	4.2	21
45	TRIM Protein-Mediated Regulation of Inflammatory and Innate Immune Signaling and Its Association with Antiretroviral Activity. Journal of Virology, 2013, 87, 257-272.	3.4	189
46	Electroencephalographic Changes Following Direct Current Deep Brain Stimulation of Auditory Cortex. Neurosurgery, 2013, 72, 267-275.	1.1	7
47	The Drosophila DmGluRA is required for social interaction and memory. Frontiers in Pharmacology, 2013, 4, 64.	3.5	14
48	Nicotine normalizes event related potentials in COMT-Val-tg mice and increases gamma and theta spectral density.. Behavioral Neuroscience, 2012, 126, 332-343.	1.2	9
49	The Electrophysiological Signature of Motivational Salience in Mice and Implications for Schizophrenia. Neuropsychopharmacology, 2012, 37, 2846-2854.	5.4	10
50	Delivery Systems and Dosing for Antipsychotics. Handbook of Experimental Pharmacology, 2012, , 267-298.	1.8	6
51	Gamma synchrony: Towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Neuropharmacology, 2012, 62, 1504-1518.	4.1	244
52	GABAB-mediated rescue of altered excitatoryâ€"inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Translational Psychiatry, 2012, 2, e142-e142.	4.8	172
53	Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia?. Genes, Brain and Behavior, 2012, 11, 740-750.	2.2	105
54	MeCP2+/â^' mouse model of RTT reproduces auditory phenotypes associated with Rett syndrome and replicate select EEG endophenotypes of autism spectrum disorder. Neurobiology of Disease, 2012, 46, 88-92.	4.4	56

#	Article	IF	Citations
55	Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Neurobiology of Disease, 2012, 47, 338-346.	4.4	69
56	Nicotine Receptor Subtype-Specific Effects on Auditory Evoked Oscillations and Potentials. PLoS ONE, 2012, 7, e39775.	2.5	21
57	cAMP Response Element Binding Protein Phosphorylation in Nucleus Accumbens Underlies Sustained Recovery of Sensorimotor Gating Following Repeated D2-Like Receptor Agonist Treatment in Rats. Biological Psychiatry, 2011, 69, 288-294.	1.3	15
58	Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers, 2011, 3, 1377-1397.	4.5	3,240
59	mGluR5-Antagonist Mediated Reversal of Elevated Stereotyped, Repetitive Behaviors in the VPA Model of Autism. PLoS ONE, 2011, 6, e26077.	2.5	146
60	What Can We Expect From Long-Acting Formulations for Schizophrenia?. Current Psychiatry Reports, 2011, 13, 243-244.	4.5	1
61	Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E962-70.	7.1	98
62	Resurgence of Long-Acting Antipsychotic Formulations. Current Psychiatry Reports, 2010, 12, 276-278.	4.5	1
63	In Vitroâ€"In Vivo Correlations of Scalable PLGA-Risperidone Implants for the Treatment of Schizophrenia. Pharmaceutical Research, 2010, 27, 1730-1737.	3.5	82
64	A rapid method for creating drug implants: Translating laboratoryâ€based methods into a scalable manufacturing process. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2010, 93B, 562-572.	3.4	28
65	Mouse model predicts effects of smoking and varenicline on event-related potentials in humans. Nicotine and Tobacco Research, 2010, 12, 589-597.	2.6	18
66	Activation of the Mitogen-activated Protein Kinase, Slt2p, at Bud Tips Blocks a Late Stage of Endoplasmic Reticulum Inheritance in Saccharomyces cerevisiae. Molecular Biology of the Cell, 2010, 21, 1772-1782.	2.1	17
67	Association of Enhanced Limbic Response to Threat With Decreased Cortical Facial Recognition Memory Response in Schizophrenia. American Journal of Psychiatry, 2010, 167, 418-426.	7.2	53
68	Ketamine Modulates Theta and Gamma Oscillations. Journal of Cognitive Neuroscience, 2010, 22, 1452-1464.	2.3	191
69	Antipsychotic Dosing and Drug Delivery. Current Topics in Behavioral Neurosciences, 2010, 4, 141-177.	1.7	5
70	Effects of the Î±4Î²2 Partial Agonist Varenicline on Brain Activity and Working Memory in Abstinent Smokers. Biological Psychiatry, 2010, 67, 715-721.	1.3	119
71	Validating Î³ Oscillations and Delayed Auditory Responses as Translational Biomarkers of Autism. Biological Psychiatry, 2010, 68, 1100-1106.	1.3	275
72	Mouse behavioral endophenotypes for schizophrenia. Brain Research Bulletin, 2010, 83, 147-161.	3.0	150

#	Article	IF	Citations
73	Working memory deficits predict short-term smoking resumption following brief abstinence. Drug and Alcohol Dependence, 2010, 106, 61-64.	3.2	169
74	Psychiatric health care provider attitudes towards implantable medication. Psychiatry Research, 2010, 177, 167-171.	3.3	2
75	Novel Environment and GABA Agonists Alter Event-Related Potentials in N-Methyl-d-aspartate NR1 Hypomorphic and Wild-Type Mice. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 308-318.	2.5	15
76	Chronic ketamine impairs fear conditioning and produces long-lasting reductions in auditory evoked potentials. Neurobiology of Disease, 2009, 35, 311-317.	4.4	43
77	Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions. Brain Research, 2009, 1294, 116-127.	2.2	111
78	Role of Î²2-containing nicotinic acetylcholine receptors in auditory event-related potentials. Psychopharmacology, 2009, 202, 745-751.	3.1	22
79	Zelrixâ„¢: A Novel Transdermal Formulation of Sumatriptan. Headache, 2009, 49, 817-825.	3.9	62
80	Profile of auditory information-processing deficits in schizophrenia. Psychiatry Research, 2009, 165, 27-37.	3.3	117
81	Varenicline Improves Mood and Cognition During Smoking Abstinence. Biological Psychiatry, 2009, 65, 144-149.	1.3	199
82	Predator odor modulates auditory event-related potentials in mice. NeuroReport, 2009, 20, 1260-1264.	1.2	11
83	PSYCHOSIS AND SCHIZOPHRENIA. , 2009, , 797-815.		1
84	Release of highly hydrophilic drugs from poly(Ïµâ€caprolactone) matrices. Journal of Applied Polymer Science, 2008, 107, 3149-3156.	2.6	15
85	Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. International Journal of Pharmaceutics, 2008, 346, 151-159.	5.2	156
86	Effect of retrieval effort and switching demand on fMRI activation during semantic word generation in schizophrenia. Schizophrenia Research, 2008, 99, 312-323.	2.0	51
87	Attitudes of patients and family members towards implantable psychiatric medication. Schizophrenia Research, 2008, 105, 279-286.	2.0	9
88	A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience, 2008, 157, 95-104.	2.3	67
89	Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains. Drug and Alcohol Dependence, 2008, 92, 217-227.	3.2	30
90	A placebo-controlled trial of modafinil for nicotine dependence. Drug and Alcohol Dependence, 2008, 98, 86-93.	3.2	31

#	Article	IF	Citations
91	In vitro and in vivo demonstration of risperidone implants in mice. Schizophrenia Research, 2008, 98, 66-78.	2.0	59
92	Deviance-elicited Changes in Event-related Potentials are Attenuated by Ketamine in Mice. Journal of Cognitive Neuroscience, 2008, 20, 1403-1414.	2.3	137
93	Constitutive activation of the G-protein subunit GÎ±s within forebrain neurons causes PKA-dependent alterations in fear conditioning and corticalArcmRNA expression. Learning and Memory, 2008, 15, 75-83.	1.3	35
94	Antipsychotic-Like Properties of Phosphodiesterase 4 Inhibitors: Evaluation of 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with Auditory Event-Related Potentials and Prepulse Inhibition of Startle. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 230-239.	2.5	55
95	Male and female mice differ for baseline and nicotine-induced event related potentials.. Behavioral Neuroscience, 2008, 122, 982-990.	1.2	15
96	Constitutive Activation of GÎ±s within Forebrain Neurons Causes Deficits in Sensorimotor Gating Because of PKA-Dependent Decreases in cAMP. Neuropsychopharmacology, 2007, 32, 577-588.	5.4	62
97	Mecamylamine blocks nicotine-induced enhancement of the P20 auditory eventâ€“related potential and evoked gamma. Neuroscience, 2007, 144, 1314-1323.	2.3	49
98	Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience, 2007, 144, 239-246.	2.3	151
99	Translating basic science to improve pharmacotherapy for nicotine dependence. Nicotine and Tobacco Research, 2007, 9, 583-598.	2.6	6
100	Translational research in medication development for nicotine dependence. Nature Reviews Drug Discovery, 2007, 6, 746-762.	46.4	142
101	Effects of Nicotine Vary Across Two Auditory Evoked Potentials in the Mouse. Biological Psychiatry, 2007, 61, 23-30.	1.3	59
102	Evaluation ofin vitro release andin vivo efficacy of mPEG-PLA-haloperidol conjugate micelle-like structures. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2007, 83B, 422-430.	3.4	11
103	Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. International Journal of Pharmaceutics, 2007, 336, 367-375.	5.2	334
104	PDE inhibitors in psychiatryâ€“future options for dementia, depression and schizophrenia?. Drug Discovery Today, 2007, 12, 870-878.	6.4	91
105	A Unique Iontophoretic Patch for Optimal Transdermal Delivery of Sumatriptan. Pharmaceutical Research, 2007, 24, 1919-1926.	3.5	43
106	Olfactory Functioning in Schizophrenia: Relationship to Clinical, Neuropsychological, and Volumetric MRI Measures. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 1444-1461.	1.3	96
107	Extended-Release Intramuscular Naltrexone. Drugs, 2006, 66, 1752-1754.	10.9	2
108	Self-face recognition and theory of mind in patients with schizophrenia and first-degree relatives. Schizophrenia Research, 2006, 88, 151-160.	2.0	173

#	Article	IF	Citations
109	Effect of drug type on the degradation rate of PLGA matrices. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 64, 287-293.	4.3	177
110	Mice expressing constitutively active GsÎ± exhibit stimulus encoding deficits similar to those observed in schizophrenia patients. Neuroscience, 2006, 141, 1257-1264.	2.3	18
111	Altered neuregulin 1â€“erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia. Nature Medicine, 2006, 12, 824-828.	30.7	528
112	Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. Psychopharmacology, 2006, 190, 201-211.	3.1	18
113	Corticosterone Modulates Auditory Gating in Mouse. Neuropsychopharmacology, 2006, 31, 897-903.	5.4	29
114	Flat Affect in Schizophrenia: Relation to Emotion Processing and Neurocognitive Measures. Schizophrenia Bulletin, 2006, 32, 279-287.	4.3	195
115	Prognostic Variables at Intake and Long-Term Level of Function in Schizophrenia. American Journal of Psychiatry, 2006, 163, 433-441.	7.2	112
116	Ketamine Produces Lasting Disruptions in Encoding of Sensory Stimuli. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 315-324.	2.5	134
117	Levels-of-Processing Effect on Frontotemporal Function in Schizophrenia During Word Encoding and Recognition. American Journal of Psychiatry, 2005, 162, 1840-1848.	7.2	100
118	Development of a New Genetic Model for Absence Epilepsy: Spike-Wave Seizures in C3H/He and Backcross Mice. Journal of Neuroscience, 2005, 25, 3452-3458.	3.6	31
119	Withdrawal from Chronic Nicotine Administration Impairs Contextual Fear Conditioning in C57BL/6 Mice. Journal of Neuroscience, 2005, 25, 8708-8713.	3.6	141
120	Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. Neuroscience, 2005, 133, 729-738.	2.3	49
121	Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. Journal of Microencapsulation, 2005, 22, 773-785.	2.8	123
122	Synthesis and Characterization of mPEGâ^'PLA Prodrug Micelles. Biomacromolecules, 2005, 6, 2708-2717.	5.4	81
123	Extended release drug delivery strategies in psychiatry: theory to practice. Psychiatry, 2005, 2, 22-31.	0.3	4
124	Effects of Chronic Olanzapine and Haloperidol Differ on the Mouse N1 Auditory Evoked Potential. Neuropsychopharmacology, 2004, 29, 739-746.	5.4	63
125	Sensorimotor Gating Deficits in Transgenic Mice Expressing a Constitutively Active Form of GsÎ±. Neuropsychopharmacology, 2004, 29, 494-501.	5.4	33
126	Patient Attitudes towards Surgically Implantable, Long-Term Delivery of Psychiatric Medicine. Neuropsychopharmacology, 2004, 29, 960-968.	5.4	21

#	Article	IF	Citations
127	The Effects of Ketamine Vary Among Inbred Mouse Strains and Mimic Schizophrenia for the P80, but not P20 or N40 Auditory ERP Components. Neurochemical Research, 2004, 29, 1179-1188.	3.3	85
128	Patient and family attitudes toward schizophrenia treatment. Current Psychiatry Reports, 2004, 6, 283-288.	4.5	3
129	Symptom and demographic profiles in first-episode schizophrenia. Schizophrenia Research, 2004, 67, 185-194.	2.0	24
130	A sexually dimorphic ratio of orbitofrontal to amygdala volume is altered in schizophrenia. Biological Psychiatry, 2004, 55, 512-517.	1.3	125
131	Phosphodiesterase inhibitors: A novel mechanism for receptor-independent antipsychotic medications. Neuroscience, 2004, 129, 101-107.	2.3	98
132	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. Journal of Clinical Investigation, 2004, 113, 1353-1363.	8.2	371
133	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. Journal of Clinical Investigation, 2004, 113, 1353-1363.	8.2	206
134	Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains. Brain Research, 2003, 992, 85-95.	2.2	54
135	Facial Emotion Recognition in Schizophrenia: Intensity Effects and Error Pattern. American Journal of Psychiatry, 2003, 160, 1768-1774.	7.2	659
136	Levels-of-processing effect on word recognition in schizophrenia. Biological Psychiatry, 2003, 54, 1154-1161.	1.3	76
137	Effects of Strain, Novelty, and NMDA Blockade on Auditory-Evoked Potentials in Mice. Neuropsychopharmacology, 2003, 28, 675-682.	5.4	103
138	Development of an Abbreviated Schizophrenia Quality of Life Scale Using a New Method. Neuropsychopharmacology, 2003, 28, 773-777.	5.4	62
139	Neurocognitive Performance and Clinical Changes in Olanzapine-Treated Patients with Schizophrenia. Neuropsychopharmacology, 2003, 28, 2029-2036.	5.4	21
140	Increased patient autonomy through long-term antipsychotic delivery systems for the treatment of schizophrenia. Expert Review of Neurotherapeutics, 2002, 2, 771-773.	2.8	4
141	Surgically Implantable Long-term Antipsychotic Delivery Systems for the Treatment of Schizophrenia. Neuropsychopharmacology, 2002, 26, 817-823.	5.4	47
142	Computerized Neurocognitive Scanning: I. Methodology and Validation in Healthy People. Neuropsychopharmacology, 2001, 25, 766-776.	5.4	344
143	Computerized Neurocognitive Scanning: II. The Profile of Schizophrenia. Neuropsychopharmacology, 2001, 25, 777-788.	5.4	157
144	Circuit-specific alterations of N-methyl-D-aspartate receptor subunit 1 in the dentate gyrus of aged monkeys.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 3121-3125.	7.1	174

#	Article	IF	Citations
145	Effects of social deprivation in prepubescent rhesus monkeys: immunohistochemical analysis of the neurofilament protein triplet in the hippocampal formation. Brain Research, 1993, 619, 299-305.	2.2	67